Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"The current CEO was behind that R/S years ago."

I wouldn't be so sure.
In any event it never happened.. The following statement appears in a number of filings in addition to the one shown:
"On February 14, 2011, the Company issued a press release stating that the issues with Mr. Evans had been settled and that the Board rescinded the authorization to affect a reverse split of its common stock."
https://www.sec.gov/Archives/edgar/data/1355250/000135525011000014/form14cr.htm


Don't let the fact that the current CEO signed the 8-k that said this throw ya:
"On November 5, 2010, shareholders holding 58%of the Registrant’s outstanding common stock adopted and approved an amendment to the Registrant’s Articles of Incorporation to effect a reverse split of the Registrant’s common stock on a 1 for 50 basis (the “Split”). The Split will be effectuated immediately upon filing the proper disclosure reports with the Commission, or anytime thereafter at the sole discretion of the Board of Directors.

The primary objective in effecting a reverse stock split is to vastly improve the Company’s capital structure, to enable the Company to raise the necessary capital to litigate or settle with George Evans, finance its continued development, and fund planned phase I studies. The Company anticipates that it will utilize the freed up equity for financing purposes as it plans to tap the capital markets for both institutional and private equity investments in the Company.


The Reverse Split will have no impact on shareholders’ proportionate equity interests or voting rights in the Company or the par value of the Company’s common stock, which will remain unchanged at $0.0001 per share.

The Board also approved the appointment of Leo Ehrlich as interim CEO, in addition to his duties as CFO.

Leo Ehrlich, interim CEO and CFO stated, ”I was surprised and disappointed to receive this email from Mr. Evans. What matters most now is Cellceutix getting through this so that our product pipeline reaches clinical trials. This Company was always built around the capabilities of Dr. Menon in developing and sourcing compounds. Dr. Menon is the bedrock of Cellceutix. Over the past three years I’ve attended many industry meetings with Dr. Menon. We’ve met with leading scientists and pharma industry executives. The feedback to me was always about the depth of knowledge and brilliance of Dr. Menon. I have never met anyone like Dr. Menon and he will continue to be the key to Cellceutix achieving its goals.”


https://www.sec.gov/Archives/edgar/data/1355250/000135525010000029/exh_99-3.htm